The use of Glauprost 0,005%, a prostaglandin analogue, in the treatment of patients with primary open angle glaucoma and its potentials for combined therapy.
We studied the hypotensive effect, tolerance and safety of the preparation Glauprost 0.005%, a prostaglandin analogue, and found that this medication can reduce IOP by 33% as compared to its initial value, which in most cases enabled us to achieve the "target" IOP level. Combined with other medications (Dorzopt 2% and Betophtan 0.5%), Glauprost 0.005% showed an additional effect enabling a lower "target" pressure when necessary. A successful IOP compensation helped stabilize and even improve perimetry data, the condition of the optic nerve and ocular hemodynamic. Local and general side effects were few, which opens prospects for long-term use of the three medications together. // Russian Ophthalmological Journal, 2012; 1:42-45.